Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel. The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina.
Recent measles outbreaks in New York City and California have many healthcare professionals concerned for their patients. According to the Center for Disease Control, measles was declared eliminated from the United States in 2000, with only an average of 60 cases of measles reported each year. But in 2013, that number increased to 189 cases.
Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol fumarate) Inhalation Solution.
Sales of specialty medicines are shifting toward hospitals and specialty pharmacies and away from independent physician owned-and-operated clinics, according to a report released Tuesday by HDMA's non-profit research foundation, The Center for Healthcare Supply Chain Research.
Upsher-Smith Laboratories on Monday announced that it has entered into a definitive agreement under which New Jersey-based Vertical Pharmaceuticals has acquired Upsher-Smith's rights to Divigel (estradiol gel) 0.1%, Nexa Plus Rx Prenatal Vitamin, and Provella, a probiotic dietary supplement.
A new analysis from Avalere Health released Monday found that consumers purchasing insurance through exchanges are twice as likely to face utilization management controls on prescription medications compared with people enrolled in employer-sponsored insurance plans.
AmerisourceBergen on Monday announced that it has reached a definitive agreement to acquire a minority stake in Profarma Distribuidora de Produtos Farmacêuticos S.A., a leading pharmaceutical wholesaler in Brazil.
Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis.